Artal Group’s Molecular Partners MOLN Stock Holding History

Artal Group’s Portfolio MOLN Stock Details MOLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100,000	Closed	-$2.05M	–	156
2021 Q2	$2.05M	Buy	+100,000	New	+$1.98M	0.04%	137

Other funds holding MOLN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Artal Group's MOLN Position: Q3 2021 in Review

Artal Group sold out of Molecular Partners (MOLN) in Q3 2021, closing a stake of 100,000 shares — an estimated $2.05M sold.

Artal Group first reported a position in MOLN in Q2 2021 and held it in 1 quarter. The position peaked at $2.05M in Q2 2021. 9 funds tracked by Wall St. Rank hold MOLN as of Q3 2021.

Artal Group reported no remaining Molecular Partners position as of Q3 2021 after selling out during the quarter.
Artal Group sold 100,000 Molecular Partners shares in Q3 2021, an estimated $2.05M.
Artal Group first reported a position in Molecular Partners in Q2 2021 and held it in 1 quarter.
Artal Group's Molecular Partners position peaked at $2.05M in Q2 2021.
9 funds tracked by Wall St. Rank held Molecular Partners as of Q3 2021.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.